Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
The Asan Foundation has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units, so each matter occupies a separate examination context.
HADDAD, MAHER M is the busiest examiner, with 1 pending matter. Prosecution work should therefore be organized around individual examiner records rather than a shared art-unit strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HADDAD, MAHER M | 1 | 50.6% | +53.8% |
| DABKOWSKI, ERINNE R | 1 | 55.8% | +68.7% |
| VOLKOV, ALEXANDER ALEXANDROVIC | 1 | 29.5% | +21.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17621451 | URINARY EXOSOME BIOMARKER FOR DIAGNOSING ANTIBODY-MEDIATED REJECTION AFTER KIDNEY TRANSPLANTATION OR PREDICTING PROGNOSIS OF PATIENT AFTER KIDNEY TRANSPLANTATION | VOLKOV, ALEXANDER ALEXANDROVIC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18325582 | Alloferon Peptide and Method Using the Same | DABKOWSKI, ERINNE R | 27d |
| 18262303 | ANTI-C4D CHIMERIC ANTIGEN RECEPTOR REGULATORY T CELLS AND USES THEREOF | HADDAD, MAHER M | — |
| 17621451 | URINARY EXOSOME BIOMARKER FOR DIAGNOSING ANTIBODY-MEDIATED REJECTION AFTER KIDNEY TRANSPLANTATION OR PREDICTING PROGNOSIS OF PATIENT AFTER KIDNEY TRANSPLANTATION | VOLKOV, ALEXANDER ALEXANDROVIC | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1654 | 1 |
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18262303 | ANTI-C4D CHIMERIC ANTIGEN RECEPTOR REGULATORY T CELLS AND USES THEREOF | HADDAD, MAHER M | 1641 | §112 | Non-Final OA | — | Pending | Jul 20, 2023 |
| 18325582 | Alloferon Peptide and Method Using the Same | DABKOWSKI, ERINNE R | 1654 | DP | Final Rejection | 27d | Pending | May 30, 2023 |
| 17621451 | URINARY EXOSOME BIOMARKER FOR DIAGNOSING ANTIBODY-MEDIATED REJECTION AFTER KIDNEY TRANSPLANTATION OR PREDICTING PROGNOSIS OF PATIENT AFTER KIDNEY TRANSPLANTATION | VOLKOV, ALEXANDER ALEXANDROVIC | 1677 | §103§112 | Final Rejection | — | Pending | Dec 21, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Asan Foundation has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Maher M Haddad has the most, with 1 of The Asan Foundation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
